SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-015806
Filing Date
2021-07-01
Accepted
2021-07-01 08:30:41
Documents
15
Period of Report
2021-07-01
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43720
2 ex99-1.htm EX-99.1 15518
3 ex99-2.htm EX-99.2 8226
  Complete submission text file 0001493152-21-015806.txt   300807

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lacq-20210701.xsd EX-101.SCH 3777
5 XBRL DEFINITION FILE lacq-20210701_def.xml EX-101.DEF 27743
6 XBRL LABEL FILE lacq-20210701_lab.xml EX-101.LAB 36816
7 XBRL PRESENTATION FILE lacq-20210701_pre.xml EX-101.PRE 26361
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5626
Mailing Address 250 WEST 57TH ST. SUITE 415 NEW YORK NY 10107
Business Address 250 WEST 57TH ST. SUITE 415 NEW YORK NY 10107 (646) 565-6940
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

IRS No.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 211064193
SIC: 2834 Pharmaceutical Preparations